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Abstract 
Purpose: Glucocorticoid receptor (GR) overexpression is associated with poor prognosis ER‑negative breast cancer. 
GR antagonism with mifepristone increases chemotherapy‑induced breast cancer cell death, therefore we conducted 
a phase I clinical trial of mifepristone and nab‑paclitaxel in advanced breast cancer.
Methods: A novel randomized phase I design was used to assess the effect of mifepristone on nab‑paclitaxel phar‑
macokinetics and toxicity. Patients were randomized to placebo or mifepristone for the first cycle; mifepristone was 
given to all for subsequent cycles.
Results: Nine patients were enrolled. All were found to have a twofold or greater increase in serum cortisol after 
mifepristone administration, reflecting effective GR inhibition. Neutropenia occurred at both nab‑paclitaxel dose 
levels studied (100 and 80 mg/m2), and was easily managed with dose reduction and/or growth factor administration. 
Pharmacokinetic data suggest an interaction between nab‑paclitaxel and mifepristone in some patients. Two patients 
had complete responses (CR), three partial responses (PR), one stable disease (SD), and three progressive disease (PD). 
Immunohistochemical staining for GR found six of nine tumors were GR‑positive. All six GR‑positive tumors were 
triple‑negative at the time of recurrence. Of these six patients, two had CRs, two PRs, one SD, and one PD.
Conclusions: GR appears to be a promising target in TNBC, and GR inhibition plus chemotherapy produces manage‑
able toxicity. While neutropenia was observed in some, a nab‑paclitaxel dose of 100 mg/m2 plus mifepristone 300 mg 
was found to be tolerable, and a randomized phase II trial of nab‑paclitaxel with/without mifepristone is planned in 
GR‑positive advanced TNBC.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The glucocorticoid receptor (GR) is expressed in a sig-
nificant subset of human breast cancers (Conzen 2008). 
In ER-negative breast cancer, but not ER-positive breast 
cancer, high GR expression in the primary tumor is asso-
ciated with a significantly higher risk of relapse (Pan 
et al. 2011). In vitro and in vivo experiments suggest that 
activation of the GR in ER-negative pre-malignant breast 
epithelial and cancer cells initiates cell survival pathways 
under otherwise apoptosis-inducing conditions (e.g. 
chemotherapy, radiation, and growth factor deprivation) 
(Wu et  al. 2004). Glucocorticoid-mediated GR activa-
tion is associated with cancer cell resistance in preclini-
cal models by activating the expression of genes whose 
protein products significantly inhibit chemotherapy-
induced apoptosis (Skor et al. 2013). We hypothesize that 
GR antagonism will enhance chemotherapy sensitivity of 
GR+/ER− breast cancer cells by blocking stress-mediated 
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cell survival pathways that would otherwise counteract 
chemotherapy-induced apoptosis in tumor cells.
Mifepristone is a potent glucocorticoid receptor (GR) 
and progesterone receptor (PR) antagonist, as well as 
a weak androgen receptor (AR) antagonist (Song et  al. 
2004). Mifepristone is currently FDA approved for the 
treatment of hyperglycemia secondary to Cushing’s dis-
ease and termination of pregnancy (Spitz and Bardin 
1993; Johanssen and Allolio 2007). While a single dose 
of 200  mg of mifepristone combined with misoprostol 
is sufficient to terminate pregnancy, studies in Cushing’s 
Syndrome suggest that higher doses may be required for 
potent anti-GR effects (Nieman et al. 1985). Animal stud-
ies suggest that GR antagonism may be of value in the 
treatment of a variety of diseases such as glucocorticoid-
dependent hypertension, arthritis, glaucoma, psychosis, 
and addiction, although clinical studies have yet to be 
reported. Several small single agent studies of mifepris-
tone and another PR antagonist onapristone have been 
evaluated for advanced breast cancer with disappointing 
results. However, these studies have been focused on use 
of these agents as PR antagonists in PR positive disease 
(Klijn et al. 2000; Romieu et al. 1987; Perrault et al. 1996; 
Bakker et al. 1990).
Taxanes and anthracyclines remain among the most 
active and widely used chemotherapy agents used to treat 
breast cancer in the adjuvant as well as metastatic set-
ting (Vishnu and Roy 2011). Paclitaxel inhibits mitosis 
and leads to cell death by binding to dimerictubulin and 
causing disruption of microtubule disassembly. Response 
rates for paclitaxel in taxane naïve patients with meta-
static breast cancer have ranged from 20 to 60 %. Weekly 
therapy appears to be more efficacious and has less 
hematologic toxicity than every-3-week dosing (Seidman 
et al. 2008). One major limitation of paclitaxel, however, 
is its poor water solubility. Due to poor solubility, pacli-
taxel must be dissolved in the solvent Cremophor. Cre-
mophor is associated with many side effects, including 
anaphylaxis, and requires premedication with glucocorti-
coids (Shepherd 2003).
Nab-paclitaxel is an albumin-bound, solvent-free novel 
formulation of paclitaxel that eliminates the need for pre-
medication with glucocorticoids. A large phase II study 
evaluating weekly nab-paclitaxel (at a dose of 100  mg/
m2 given weekly for 3  weeks out of 4) demonstrated 
response rates of 14–16 % in taxane-resistant, previously 
treated metastatic breast cancer patients (Blum et  al. 
2007). While nab-paclitaxel is an effective and well-tol-
erated therapy for MBC, many tumors do not respond to 
therapy, and even those that do initially respond eventu-
ally go on to develop resistance.
We hypothesized that GR antagonism with mife-
pristone prior to the administration of cytotoxic 
chemotherapy will improve efficacy by blocking the 
strong anti-apoptotic signal mediated by GR activation 
via circulating endogenous cortisol. Here we present 
the first clinical trial combining a glucocorticoid recep-
tor (GR) antagonist with nab-paclitaxel. Nab-paclitaxel 
was used instead of paclitaxel, as it does not require 
glucocorticoid premedication, which would counter 
the GR antagonism of mifepristone. As paclitaxel (and 
therefore nab-paclitaxel) is a known CYP2C8 substrate, 
and mifepristone is a known inhibitor of CYP2C8, co-
administration of the two drugs had the potential to 
increase paclitaxel levels. We therefore utilized a rand-
omized phase I design to assess the impact of mifepris-
tone on paclitaxel pharmacokinetics and toxicity. The 
purpose of the trial was to study the safety and tolerabil-
ity of the combination and determine the recommended 
phase II dose of the combination of mifepristone plus 
nab-paclitaxel.
Methods
This study was conducted at The University of Chi-
cago Medicine (Chicago, IL) and Northshore Univer-
sity HealthSystem (Evanston, IL), and was approved 
by the respective Institutional Review Boards. Written 
informed consent was obtained prior to any study proce-
dures. The study was registered on ClinicalTrials.gov as 
NCT01493310.
Eligibility criteria
Patients were eligible for this study if they had metastatic 
or locally advanced breast cancer not amenable to local 
therapy, were ≥18  years of age, had an ECOG PS ≤  2. 
Measurable disease was not required. Patients with ER 
and/or PR positive disease must have progressed on at 
least one prior hormonal therapy. Patients were required 
to have normal organ and marrow function.
Exclusion criteria
Patients were excluded from this study if they had a his-
tory of allergy or hypersensitivity to mifepristone, pacli-
taxel, or drugs of similar chemical composition, had 
received more than four prior cytotoxic therapies for 
metastatic disease, or prior nab-paclitaxel or mifepris-
tone for metastatic disease. Patient who were pregnant or 
breast feeding, had peripheral neuropathy > grade 1, had 
long term or concurrent use of corticosteroid therapy, 
or had significant uncontrolled intercurrent illness were 
also excluded. A washout period of 4 weeks was required 
before initiation of therapy.
Drug supply
Nab-paclitaxel was obtained commercially in single-dose 
vials (manufactured by Celgene). Mifepristone (300  mg 
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tablets) and matching placebo tablets were supplied by 
Corcept Therapeutics.
Study treatment
Treatment was administered on an outpatient basis. 
No concomitant investigational or commercial agents 
or therapies administered with the intent to treat the 
patient’s malignancy were allowed, with the exception 
of bisphosphonates (e.g. zoledronic acid) and RANKL 
inhibitors (e.g. denosumab) for patients with bone 
metastases.
Patients were randomized to nab-paclitaxel plus mife-
pristone versus nab-paclitaxel plus placebo treatment 
during the first cycle of each dose level in a 3:2 ratio 
(with a planned minimum of five patients per dose level). 
Treatment assignment was double-blinded to ensure 
that stress (which might elevate serum cortisol levels) 
between treatment group was equivalent, and to ensure 
unbiased assessment of adverse events attributable to 
treatment. Only patients randomized to mifepristone 
were used for toxicity assessment and determination of 
mifepristone dose escalation. Patients were unblinded at 
the end of cycle 1, and placebo patients were crossed over 
to mifepristone treatment at the current dose level begin-
ning in cycle 2.
Patients were treated with intravenous weekly nab-
paclitaxel on day 1, 8 and 15 of each 28  day cycle at a 
starting dose of 100  mg/m2. Mifepristone was adminis-
tered orally for two consecutive days, starting one day 
prior to each nab-paclitaxel infusion at a starting dose of 
300 mg per day.
Dose escalation/de‑escalation
A novel randomized phase I design was utilized, although 
the mifepristone dose escalation was to follow the tradi-
tional ‘3 +  3’ design with up to four dose cohorts (300, 
600, 900, and 1200 mg) to determine the maximally tol-
erated dose (MTD). The starting dose of mifepristone 
was 300 mg. Toxicity was assessed weekly during the first 
cycle of therapy and on day 1 of cycle 2. Adverse events 
were assessed among all patients, but only mifepristone 
patients’ adverse events during cycle 1 were used for the 
purposes of dose-escalation decisions.
The nab-paclitaxel starting dose was 100 mg/m2 (dose 
level 1), with the plan to de-escalate to 80 mg/m2 (dose 
level −1) and 60  mg/m2 (dose level −2) for subsequent 
dose levels as needed.
Dose‑limiting toxicity (DLT)
Dose-limiting toxicity was defined as any grade III toxic-
ity not reversible to grade II or less within 96  h, or any 
grade IV toxicity (excluding nausea and vomiting). Tox-
icity was graded according to CTCAE version 4.0. A 
patient who received any amount of drug was considered 
evaluable for toxicity. However, patients who did not 
receive at least five of the six doses of mifepristone and all 
of the three planned doses of nab-paclitaxel during cycle 
1 for reasons other than toxicity/tolerability, were con-
sidered inevaluable for determination of MTD and were 
replaced. A dose reduction, omission, or delay of dose for 
toxicity performed during cycle 1 or on day 1 of cycle 2 
constituted a DLT.
Study assessments
The patient’s medical history was taken at baseline. A 
physical examination, ECOG status assessment, com-
plete blood count with differential, and a comprehen-
sive metabolic panel were conducted at baseline and 
weekly for 3 weeks in a row with 1 week off though out 
the treatment period. All adverse events and laboratory 
abnormalities were assessed at baseline and during treat-
ment. Antitumor activity was evaluated every 2 cycles 
(8 weeks).
Pharmacokinetic analyses
Paclitaxel concentrations were determined on cycle 1, 
days 2 and 9 for all patients. Paclitaxel concentrations 
were also determined on cycle 2, days 2 and 9 for patients 
randomized to placebo for cycle 1, who then crossed over 
to mifepristone for cycle 2. In addition to a baseline pacli-
taxel concentration prior to nab-paclitaxel administra-
tion (on day 1 and day 8), concentrations were measured 
24 and 28 h after nab-paclitaxel administration on days 2 
and 9. Because mifepristone can inhibit its own metabo-
lism, mifepristone trough concentrations were meas-
ured on plasma sampled on days 1 and 8 of cycle 1 (just 
prior to day 1 and 8 mifepristone dose administration). 
For paclitaxel sample collection, 7  ml of whole blood 
were placed in a heparin vacutainer and centrifuged at 
2000 rpm for 15 min. Plasma was transferred to a cryo-
vial and stored at −80 °C. Whole blood for mifepristone 
levels was drawn in 7  ml heparin vacutainers, inverted 
gently 10 times then immediately centrifuged at 2000×g 
for 15  min with 1  ml of plasma aliquoted to cryotubes 
then frozen upright at −20  °C. Paclitaxel concentration 
assays were performed by The University of Chicago 
Pharmacology Core Facility, and mifepristone concentra-
tion assays were performed by Microconstants, Inc (La 
Jolla, CA).
Correlative studies
To verify GR blockade, levels of both ACTH and cortisol 
were drawn at baseline prior to the initiation of mifepris-
tone/placebo and nab-paclitaxel, and on day 1 of cycle 
1, after a single dose of mifepristone. For patients rand-
omized to placebo for cycle 1, both ACTH and cortisol 
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were drawn on day 1 of cycle 2 as well. Because there are 
diurnal variations in ACTH and serum cortisol levels, 
both samples were obtained between 8 am and 10 am.
Unstained sections (3–5 microns in thickness) of pri-
mary tumor or metastatic tumor or both were requested 
for each patient enrolled on study. GR and androgen 
receptor (AR) nuclear expression were determined ret-
rospectively via immunohistochemical (IHC) examina-
tion of archival tissue obtained for all patients enrolled. 
For determination of GR expression, anti-GR XP anti-
body (Cell Signaling, D8H2, 1:40 dilution) was used, and 
for determination of AR expression, anti-AR antibody 
(DAKO, AR441, 1:300 dilution) was used. Staining with 
these antibodies was performed according to methods 
previously published by Belova et al. (Belova et al. 2009). 
Tumors were considered GR or AR positive if greater 
than 10 % of cancer cells stained positively for nuclear GR 
or AR, respectively.
Statistical analysis
This was a randomized, double-blinded, phase I, dose-
escalation clinical trial of mifepristone versus placebo 
with nab-paclitaxel for metastatic or locally advanced 
breast cancer patients. For each dose level, 5 patients 
were randomized to nab-paclitaxel plus mifepristone 
versus nab-paclitaxel plus placebo in a 3:2 ratio for the 
first cycle of treatment. Patients were unblinded at the 
end of cycle 1 and crossed over to mifepristone begin-
ning in cycle 2. Dose-escalation proceeded according to 
the standard ‘3 +  3’ design among patients randomized 
to mifepristone.
Pharmacokinetic samples were collected in order to 
determine whether the addition of mifepristone alters 
the pharmacokinetics of nab-paclitaxel. Serum samples 
for pharmacokinetic analyses were collected from all 
patients at baseline; cycle 1, day 2 (C1D2); cycle 1, day 
9 (C1D9); and additional samples were collected from 
patients randomized to placebo on cycle 2 day 2 (C2D2); 
and cycle 2, day 9 (C2D9). Due to the small number of 
patients enrolled, pharmacokinetic data were summa-
rized using graphical methods. We used the Wilcoxon 
rank sum test to compare continuous variables between 
groups. Linear regression models were used to determine 
the relationship between continuous measures; normality 




A total of nine women were enrolled between December 
of 2011 and March of 2013. The median age of partici-
pants was 56 years (range 47–74). Clinical and response 
characteristics are shown in Table 1. Of the nine patients 
enrolled, all but one had received prior taxane-based 
chemotherapy, seven in the adjuvant setting, and one in 
both the adjuvant and metastatic disease settings. How-
ever, only one patient was taxane-refractory, defined 
as recurrence or progression within 6  months of prior 
taxane exposure. Eight of the nine patients had relapsed 
after adjuvant therapy, and one presented with de novo 
metastatic disease.
Dose‑limiting toxicities
Because of the potential for cumulative toxicity from 
nab-paclitaxel, only those patients randomized to mife-
pristone for cycle 1 were used for DLT determination (see 
Table 2). Of the 4 patients treated at dose level 1, patients 
2 and 4 received mifepristone cycle 1 and were evaluable 
for DLT. Both patients experienced dose-limiting neutro-
penia. Patient 2 discontinued study treatment after cycle 
2 for rapid progression of disease. Patient 4 remained 
on study treatment for 4 cycles with nab-paclitaxel dose 
reduction and filgrastim growth factor support, but 
discontinued treatment after four cycles for persistent 
neutropenia.
Because two DLTs were observed at dose level 1, the 
starting dose of nab-paclitaxel was reduced from 100 
to 80  mg/m2 for dose level −1 (again, given weekly for 
3 weeks in a row followed by a 1 week break). The mife-
pristone dose was continued at 300 mg/d the day prior to 
and the morning prior to nab-paclitaxel administration. 
Of the 5 patients treated at dose level −1, patients 5, 6, 
and 9 received mifepristone for cycle 1 and were evalu-
able for DLT. Patients 5 and 9 both experienced a dose-
limiting neutropenia. Patient 6 did not experience a DLT. 
Patient 5 was able to continue on therapy for 10 cycles 
with a dose reduction of the nab-paclitaxel to 60  mg/
m2 and the initiation of growth factor support. She ulti-
mately came off of study after 10 cycles for neuropathy, 
and continued on single agent nab-paclitaxel for an addi-
tional 19 cycles at a further reduced dose and a modified 
schedule. Patient 6 received 4 cycles of therapy and ulti-
mately came off of study after four cycles for PD. After 
cycle 2, her nab-paclitaxel dose was reduced to 60 mg/m2 
secondary to neuropathy. Patient 9 was found to have PD 
after 2 cycles.
Common grade 1 toxicities observed on the study 
included fatigue, nausea, vomiting, constipation, diar-
rhea, anorexia, rash, and arthralgias. The only grade 
2 toxicities observed were alopecia and sensory 
neuropathy.
The majority of patients who received growth factor 
support received 2–3 days of filgrastim, with rapid recov-
ery of their counts. However, due to the DLT of neutro-
penia observed at both nab-paclitaxel dose levels (100 
and 80 mg/m2), and the possibility that the neutropenic 
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DLTs were a result of a pharmacokinetic drug–drug 
interaction between nab-paclitaxel and mifepristone 
leading to increased plasma paclitaxel concentrations, a 
decision was made to close the study and proceed with 
pharmacokinetic analysis.
To explore the possibility of a pharmacodynamic (PD) 
interaction between mifepristone and nab-paclitaxel, we 
looked at the relationship between the log-fold reduc-
tion in the absolute neutrophil count (ANC) during cycle 
1 and the randomized treatment. We found that patients 
randomized to mifepristone for cycle 1 had a greater log-
fold reduction in ANC as compared to those who were 
randomized to placebo (see Additional file  1: Figure 
S1A, p =  0.05). A similar analysis of log-fold reduction 
in ANC and nab-paclitaxel dose level (100 vs. 80  mg/
m2), showed no dose effect (see Additional file 1: Figure 
S1B, p = 0.46). We also used a linear regression model to 
determine the relationship between log-fold ANC reduc-
tion and 24-h paclitaxel concentration, and found that 
ANC decreases by approximately 5.5  % for a 10  ng/mL 
increase in paclitaxel concentration (p = 0.04). Although 
limited by the small sample size, we did not find that this 
relationship was different between placebo and mifepris-
tone randomized patients (p = 0.94, paclitaxel concentra-
tion by treatment interaction). Similarly, no interaction 
was found between paclitaxel concentration and dose 
groups (p = 0.87).
Tumor and response characteristics
Of the nine patients treated on study overall, two patients 
had a CR, three a PR, one SD, and three PD. Four patients 
were treated at dose level 1 (100  mg/m2 of nab-pacli-
taxel + mifepristone 300 mg), and five at dose level −1 
(80 mg/m2 of nab-paclitaxel + mifepristone 300 mg). Of 
the four patients treated at dose level 1, one had a com-
plete response (CR), one had a partial response (PR), and 
two had progression of disease (PD). Of the five patients 
treated at dose level −1, one had a CR, two had a PR, one 
had stable disease (SD, unconfirmed), and one had PD. 
As outlined in Table  3, while five of the study partici-
pants had estrogen receptor (ER) positive disease at the 
time of initial diagnosis, all but one of the patients had 
triple-negative disease at the time of recurrence (patient 
3 had ER-positive disease at initial diagnosis, and did 
not undergo a biopsy of a metastatic site at the time of 
recurrence).
Glucocorticoid receptor (GR) and androgen recep-
tor (AR) expression was determined using immunohis-
tochemical staining (see Fig.  1). As mifepristone is not 
Table 1 Clinical characteristics and response
PR partial response, PD progressive disease, CR complete response, SD stable disease, MBC metastatic breast cancer, Txs treatments, n/a not available, Y yes, N no
a In the adjuvant setting, with exception of patient 4 who received taxane in both adjuvant and metastatic disease setting
b Defined as recurrence or progression within 6 months of taxane exposure
c Unconfirmed response, all other responses confirmed
Patient Cycle 1 randomization # Prior Txs for MBC Prior taxanea Taxane refractoryb Best response
Dose level 1: nab‑paclitaxel 100 mg/m2 + mifepristone 300 mg
 1 Placebo 0 N N/A PR
 2 Mifepristone 0 Y N PD
 3 Placebo 2 Y N PD
 4 Mifepristone 2 Y N CR
Dose level −1: nab‑paclitaxel 80 mg/m2 + mifepristone 300 mg
 5 Mifepristone 0 Y N PR
 6 Mifepristone 0 Y Y SDc
 7 Placebo 0 Y N CR
 8 Placebo 3 Y N PR
 9 Mifepristone 3 Y N PD
Table 2 Dose limiting toxicities in  patients randomized 
to mifepristone for cycle 1
Only patients randomized to mifepristone for cycle 1 were used for DLT 
determination
M denotes patients randomized to mifepristone for cycle 1
Y yes, N no
Patient DLT Type of DLT
Dose level 1: nab‑paclitaxel 100 mg/m2 + mifepristone 300 mg
 2‑M Y Neutropenia
 4‑M Y Neutropenia
Dose Level −1: nab‑paclitaxel 80 mg/m2 + mifepristone 300 mg
 5‑M Y Neutropenia
 6‑M N None
 9‑M Y Neutropenia
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only a strong GR and PR antagonist, but also a weak AR 
antagonist, we also wanted to determine AR expression 
of the tumors and perform an exploratory correlation of 
expression of both GR and AR to response. GR and AR 
staining was performed on both the primary tumor and 
the recurrence (when available). For the seven tumor 
pairs where both the primary tumor and the recur-
rent tumor were available (patient 1 presented with de 
novo metastatic disease, and patient 3 did not undergo 
a biopsy of a metastatic site at the time she developed 
disease recurrence), there was concordance between the 
primary and the recurrent tumors for both GR and AR. 
Six tumors were GR-positive (five strongly positive, one 
weakly positive). Of the five patients with strongly GR-
positive tumors, two had a CR, 2 had a PR, and one had 
SD (unconfirmed). One additional patient had a tumor 
that was weakly GR-positive; she experienced PD after 
two cycles of study therapy (patient 9). Four tumors were 
positive for AR; two were strongly positive and two were 
weakly positive. Of the two patients with strongly AR-
positive tumors, one had a PR and one had PD. No tumor 
was strongly positive for both GR and AR.
Of the four patients who had TNBC at the time of ini-
tial diagnosis, all responded to therapy (one had a CR, 
and three had PRs). Of these four patients, three had 
tumors that were GR-positive/AR-negative, and one had 
a tumor which was AR-positive/GR-negative.
Pharmacokinetics
Plasma concentrations of paclitaxel for all patients are 
shown in Additional file 2: Table S1, and plasma mifepris-
tone (and its active metabolites) concentrations are shown 
in Additional file 2: Table S2. For patient 1, who received 
placebo for cycle 1 and then went on to receive mifepris-
tone for cycle 2, paclitaxel concentrations were similar in 
both cycles. For patient 3, however, paclitaxel concentra-
tions were higher when mifepristone was administered 
with nab-paclitaxel compared to when nab-paclitaxel was 
given with placebo. Figure 2a shows paclitaxel concentra-
tions over time for all patients who received placebo for 
cycle 1 and then went on to receive mifepristone for cycle 
2. Patient 3 was the only patient with significantly higher 
plasma paclitaxel concentrations when mifepristone was 
administered with nab-paclitaxel as compared to nab-
paclitaxel alone. When evaluating paclitaxel concentrations 
Table 3 Tumor and response characteristics
P denotes patients randomized to placebo for cycle 1 with cross over to mifepristone for cycle 2
M denotes patients randomized to mifepristone for cycle 1
ER estrogen receptor, PR progesterone, receptor, AR androgen receptor, GR glucocorticoid receptor, 1° primary, met metastatic, wk weak, n/a not available
a Performed on both primary and metastatic tumor (when available) and were concordant
b Radiographically unconfirmed
Patient ER 1° PR 1° ER met PR met GRa ARa Best Response # of cycles Reason for discontinuation
1‑P n/a n/a − − + − PR 6 Neuropathy
2‑M + + − − − wk+ PD 2 PD
3‑P + + n/a n/a − − PD 2 PD
4‑M + + − − + wk+ CR 4 Neutropenia
5‑M − − − − + − PR 10 Neuropathy
6‑M + − − − + − SDb 4 PD
7‑P − − − − + − CR 9 PD
8‑P − − − − − + PR 5 Neuropathy
9‑M + + − − wk+ + PD 2 PD
Fig. 1 Immunohistochemical staining for GR and AR in primary 
breast tumors. a Tumor cells staining positively for GR. b tumor cells 
staining negative for GR (note that stromal cells stain positively for 
GR). c Tumor cells staining positive for AR. d Tumor cells staining 
negative for AR. AR androgen receptor, GR glucocorticoid receptor. a, 
d Tumors from patient 7. b, c Tumors from patient 8
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over time by dose level (Fig. 2b), when nab-paclitaxel was 
administered with mifepristone, the patients with the 
three highest concentrations were treated at dose level 1 
(100  mg/m2 of nab-paclitaxel), while those who received 
80 mg/m2 had lower plasma paclitaxel concentrations.
Plasma mifepristone concentrations, as well as its active 
metabolites, were evaluated on days 1 and 8 for cycle 1 
in all patients, and during cycle 2 in those patients rand-
omized to placebo for cycle 1. For those patients receiv-
ing placebo for cycle 1, plasma mifepristone levels were 
undetectable, as expected (see Additional file  2: Table 
S2). No consistent increase of mifepristone levels were 
seen in the second cycle relative to the first. The concen-
tration of mifepristone (C-1073) and its active metabo-
lites (RU42633, RU42698, and RU42848) were higher on 
day 1 than 8 in some patients, and lower in others.
Analysis of cortisol and ACTH
Serum cortisol and ACTH were evaluated at base-
line and again 24  h after a single dose of mifepristone 
300  mg or placebo on day 1 of cycle 1. For those rand-
omized to placebo for cycle 1, cortisol and ACTH values 
were also determined on day 1 of cycle 2. When placebo 
was administered for cycle 1, cortisol and ACTH levels 
remained unchanged. After a single dose of mifepris-
tone, serum cortisol levels increased 2–3 fold (Additional 
file  1: Figure S2A), demonstrating effective GR inhibi-
tion. ACTH levels did not increase uniformly: for some 
patients ACTH levels remained relatively unchanged, 
and in others, they increased 2–3 fold, suggesting that the 
peak ACTH response in some individuals had occurred 
prior to the 24 h serum collection (Additional file 1: Fig-
ure S2B).
Discussion
The primary objective of this study was to determine the 
safety and tolerability of the combination of the GR ste-
roidal antagonist mifepristone and nab-paclitaxel. We 
also sought to confirm that systemic GR antagonism was 
occurring with the mifepristone dose used in this trial. 
Dose-limiting neutropenia (as specified in the protocol) 
was observed at both doses of nab-paclitaxel; therefore, 
we halted the study and analyzed the pharmacokinetic 
data for a potential drug–drug interaction. The novel 
randomized design we used allowed us the opportunity 
to understand how mifepristone impacted nab-paclitaxel 
clearance in the same patient, as those patients who were 
randomized to placebo for cycle 1 crossed over to receive 
mifepristone for cycle 2. Data from the pharmacokinetic 
studies suggest that for some patients, there appeared 
to be a delay in paclitaxel clearance when co-adminis-
tered with mifepristone (see Fig. 2a, b). For the remain-
ing patients, there was no clear evidence of a drug–drug 
interaction, and paclitaxel concentrations 24  h after 
administration were consistent with levels observed in 
initial phase I studies of nab-paclitaxel (Nyman et  al. 
2005; Ando et al. 2012).
The neutropenia observed in this phase I trial, while 
dose-limiting by protocol definition, was safe and man-
ageable, and the majority of patients who experienced 
neutropenia continued to receive study treatment with 
dose delays, dose modifications, and/or the institution 
of growth factor support. Most of the five patients who 
received growth factor support received 2–3 days of once 
daily filgrastim, with rapid recovery of their counts. Of 
the nine patients studied, four did not experience neu-
tropenia, and thus did not require dose modifications 
or growth factor support. Of the five who did experi-
ence neutropenia, one discontinued study treatment due 
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Fig. 2 Plasma paclitaxel concentrations at 24 and 28 h. a Patients 
1, 3, 7, and 8 were randomized to placebo/nab‑paclitaxel during C1. 
Patients 1, 7, and 8 had no significant increase in paclitaxel levels 
when treated with mifepristone/nab‑paclitaxel in C2. However, 
patient 3 had higher paclitaxel levels in C2 when treated with 
mifepristone/nab‑paclitaxel. b patients treated at dose level 1 (nab‑
paclitaxel 100 mg/m2) had higher plasma paclitaxel concentrations 
than those patients treated at dose level −1 (nab‑paclitaxel 80 mg/
m2). C1 cycle 1, C2 cycle 2
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and dose modification (patient 4), with the other four 
remaining on study therapy with the assistance of growth 
factor support. Of note, patient 4 continued to have neu-
tropenia on nab-paclitaxel even after the discontinuation 
of mifepristone, and had to discontinue nab-paclitaxel 
therapy completely due to persistent neutropenia despite 
dose reduction and the institution of growth factor sup-
port. Of the other four, only one also required a dose 
reduction for the management of neutropenia (patient 5), 
but she was able to stay on study therapy for 10 cycles, 
before coming off for neuropathy.
To explore if there was a pharmacodynamic interac-
tion between mifepristone and nab-paclitaxel (leading to 
a decreased neutrophil count), we compared the log-fold 
reduction in ANC for those randomized to mifepristone 
for the first cycle of therapy to those randomized to pla-
cebo. While we did see a greater log-fold reduction in 
ANC when mifepristone was given compared to placebo, 
this correlation was borderline significant. However, some 
cases of neutropenia observed in this trial did not appear 
to be the result of delayed nab-paclitaxel clearance. The 
greater log-fold reduction seen when mifepristone was 
administered with nab-paclitaxel as compared to placebo 
is suggestive of a pharmacodynamic interaction between 
mifepristone and nab-paclitaxel leading to neutropenia.
We hypothesize that some cases of neutropenia 
observed in this study may be related to the enhancement 
of chemotherapy-induced neutrophil apoptosis in the 
setting of a GR antagonist, and not delayed clearance of 
nab-paclitaxel. Paclitaxel levels observed in this trial were 
consistent with those levels observed in other trials using 
similar doses of nab-paclitaxel, further suggesting a phar-
macodynamic mechanism for the neutropenia, rather 
than a simple pharmacokinetic increase in paclitaxel lev-
els. Glucocorticoids have been shown to protect neutro-
phils from apoptosis (Kato et  al. 1995). In the setting of 
GR antagonists, it is possible that neutrophils will be more 
susceptible to cell death, particularly in the setting of 
apoptosis-inducing cytotoxic therapies such as nab-pacli-
taxel. As such, combining GR antagonism with chemo-
therapy in general may require growth factor support. As 
some patients did not develop neutropenia, it is likely that 
dose modifications and growth factor support will need to 
be individualized based on observed toxicities.
In an exploratory analysis evaluating tumor GR and 
AR expression, we observed that tumors with strong GR 
expression were typically AR-negative, and tumors with 
strong AR expression were typically GR-negative. Expres-
sion of BR is negatively regulated by AR signaling in pros-
tate cancer (Xie et al. 2015), and our data suggest that this 
this is likely the case in breast cancer as well. Six patients 
had tumors that were GR-positive (five were strongly GR-
positive, and one was weakly GR-positive), and all six of 
these tumors were triple-negative at the time of recur-
rence (two of these patients initially presented with ER-
positive disease, but tumors had converted to TNBC at 
the time of disease recurrence). Interestingly, of the five 
patients with GR strongly-positive tumors, four patients 
had a response to therapy (two CRs and two PRs, all con-
firmed), and one had SD (unconfirmed). The patient with 
GR weakly-positive disease progressed rapidly. These 
observational data support our hypothesis that GR-posi-
tive TNBC may benefit from the addition of a GR antago-
nist to chemotherapy.
In conclusion, nab-paclitaxel plus mifepristone appears 
to be a tolerable regimen, with a primary toxicity of neu-
tropenia. While neutropenia was a protocol-defined DLT, 
the combination of mifepristone and nab-paclitaxel at 
both dose levels studied was tolerable, and the neutro-
penia was easily managed. It also appears that the inter-
action between mifepristone and nab-paclitaxel is not 
necessarily pharmacokinetic in nature, but rather phar-
macodynamic. Thus, given the ease of management of 
the neutropenia and the promising efficacy of the com-
bination, we are proceeding with a randomized phase 
II trial of nab-paclitaxel with mifepristone versus pla-
cebo in patients with advanced, GR positive, triple-neg-
ative breast cancer. We will use a nab-paclitaxel dose of 
100 mg/m2 given 3 weeks on followed by 1 week off, with 
a mifepristone dose of 300 mg given the day before and 
the day of each nab-paclitaxel dose. As neutropenia was 
not observed in all patients, even at the higher dose level 
used, we will use the standard dose of 100  mg/m2, the 
standard dose used in the metastatic setting.
Additional files
Additional file 1. Figure S1. Log‑fold reduction in absolute neutrophil 
count by mifepristone versus placebo or by dose level. A, in general, 
patients administered mifepristone/nab‑paclitaxel had a greater reduction 
in absolute neutrophil count (ANC) compared to placebo/nab‑paclitaxel 
(p = 0.05). The gray solid line represents the average linear regression of 
log‑fold reduction in ANC for patients receiving placebo/nab‑paclitaxel. 
The solid black line represents the average linear regression of log‑fold 
reduction in ANC for patients receiving mifepristone/nab‑paclitaxel. The 
dashed line represents the averaged linear regression for all patients. B, 
there was no significant difference in ANC reduction between patients 
who received nab‑paclitaxel dose level 1 (100 mg/m2) compared to dose 
level ‑1 [nab‑paclitaxel 80 mg/m2 (p = 0.46)]. The gray solid line represents 
the linear regression of log‑fold reduction in ANC in patients receiving 
nab‑paclitaxel 100 mg/m2. The solid black line represents the aver‑
age linear regression of log‑fold reduction in ANC in patients receiving 
nab‑paclitaxel 80 mg/m2. The dashed line represents the averaged linear 
regression for all patients. Reg, regression lines. ANC, absolute neutrophil 
count. Figure S2: Serum cortisol and ACTH levels before therapy initiation 
and 24 h after the first dose of mifepristone 300 mg (n = 9) 1. A, serum 
cortisol levels increased by 2–3 fold in every patient. B, ACTH increases 
were variable. DL, dose level.
Additional file 2. Table S1. Plasma paclitaxel concentrations (ng/mL)**. 
Table S2: Concentrations of mifepristone and its active metabolites (ng/
mL).
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